タイラ　ナルト   Naruto Taira   平　成人    所属   川崎医科大学  医学部 臨床医学　乳腺甲状腺外科学    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
掲載誌名	正式名：PloS one 略　 称：PLoS One ISSNコード：19326203/19326203
掲載区分	国外
巻・号・頁	17(11),pp.e0278344
著者・共著者	Kikawa Yuichiro, Hagiwara Yasuhiro, Fujisawa Tomomi, Araki Kazuhiro, Iwamoto Takayuki, Sangai Takafumi, Shien Tadahiko,Takao Shintaro, Nishimura Reiki, Takahashi Masato, Toyama Tatsuya, Aihara Tomohiko, Mukai Hirofumi, Taira Naruto
担当区分	最終著者
発行年月	2022/11
概要	BACKGROUND:The HORSE-BC study previously demonstrated that second-line endocrine therapy (ET) for patients with acquired endocrine-resistant metastatic breast cancer (MBC) still provided a clinically meaningful benefit. Herein, we investigated the health-related quality of life (HRQOL) in the HORSE-BC study.METHODS:Patients with acquired endocrine-resistant MBC who were scheduled for second-line ET were recruited. The HRQOL was assessed at baseline, and 1 and 3 months after second-line ET initiation. To investigate the minimally important difference (MID) in the Functional Assessment of Cancer Therapy-Endocrine Symptoms (FACT-ES), we evaluated the means and standard deviations for the distribution-based method, and differences in the change in HRQOL for the anchor-based method. We also investigated the association between FACT-ES total scores and clinical benefit.RESULTS:Overall, 56 patients were enrolled. Of these, 47 were analyzed. When defined as 1/3 standard deviation estimates based on the distribution method, the calculated MID was 5.9. The MIDs of the FACT-ES total scores based on the anchor method were 7.7 for decline and 4.1 for improvement. The MID decline proportions were 6.1% and 14.7% lower in patients who experienced clinical benefits than in those who did not at 1 and 3 months, respectively. The ratios of MID improvement in patients who experienced clinical benefits were 18.3% and 3.2% higher, respectively; the mean change in the FACT-ES total score from baseline improved in patients who experienced clinical benefits.CONCLUSIONS:Maintaining the HRQOL as determined by FACT-ES may be associated with clinical benefits in patients with acquired endocrine-resistant MBC treated with ET.
DOI	10.1371/journal.pone.0278344
PMID	36445924